â– LECTURE OVERVIEW: Benign Prostatic Hyperplasia (BPH) is an age-related, non-malignant proliferation of the prostatic stromal and epithelial cells.
â– PATHWAY ANALYSIS:
1. Transition Zone: Hyperplasia occurs selectively in the central periurethral Transition Zone, compressing the prostatic urethra and obstructing urine outflow.
2. Dihydrotestosterone (DHT) Influence: Driven by DHT, synthesized from testosterone by 5-alpha-reductase in prostatic stromal cells.
3. Lower Urinary Tract Symptoms (LUTS): Presents with urinary frequency, urgency, nocturia, a weak urinary stream, hesitancy, and incomplete emptying.
4. Pharmacotherapy Approaches:
- Alpha-1 Adrenergic Blockers: Selectively block alpha-1A receptors on the prostatic urethra and bladder neck, relaxing smooth muscle to rapidly improve urine flow.
- 5-Alpha-Reductase Inhibitors: Block 5-alpha-reductase, preventing testosterone's conversion to DHT to shrink the prostate over 6-12 months.
â– THERAPEUTIC TARGETS & MANAGEMENT:
Primary pharmacological intervention aims to restore physiological homeostatic balance. This is achieved by either competitively blocking receptor sites, allosterically inhibiting enzymes, or supplementing missing metabolic products.
â– PHARMACODYNAMIC TARGET ENGAGEMENT:
Receptor binding dynamics dictate the overall speed, duration, and magnitude of physiological responses to therapeutic agents.
[HY-BOARD-1364]
🌟 Dynamic Clinical Key:
Alpha-1 blockers (e.g., Tamsulosin, Silodosin) provide rapid symptom relief but do not shrink the prostate. 5-alpha-reductase inhibitors (e.g., Finasteride, Dutasteride) are used for long-term reduction of prostate size, helping to prevent acute urinary retention. Absolute contraindications include pregnancy, renal insufficiency, or concurrent use of metabolic inhibitors. Watch closely for ligand-receptor saturation effects and subsequent tolerance or resistance.